U.S. drug regulators granted Eli Lilly’s COVID-19 antibody drug an emergency-use authorization on Monday, widening access to a therapy that has shown improvement in treating patients with mild to moderate cases of the CCP (Chinese Communist Party) virus.
The Food and Drug Administration (FDA) cleared the use of Eli Lilly’s neutralizing antibody LY-CoV555 for people 12 and older with mild to moderate cases of COVID-19, the disease caused by the CCP virus. The experimental therapy, called bamlanivimab, is a one-time treatment administered through an IV.